Genmab’s Arzerra approved for extended use in CLL
The Genmab-developed leukemia drug Arzerra has won a new approval from the FDA. It could counter a recent drop in sales for the product, says an analyst.
BY LOUISE WENDT JENSEN
Biotech company Genmab said Wednesday that the US Food and Drug Administration (FDA) has cleared its oncology product Arzerra (ofatumumab) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Jefferies sees strategic rationale for Genmab sale
For abonnenter
Genmab’s sBLA for Arzerra granted Priority Review
For abonnenter
